Claritas Pharmaceuticals, Inc. (CLAZF)
OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: May 19, 2025

Claritas Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2020FY 2019FY 2018FY 2017FY 20162015
Period Ending
Sep '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 2015
Selling, General & Admin
1.571.873.663.353.133.45
Upgrade
Research & Development
-2.06-2.065.797.751.671.62
Upgrade
Operating Expenses
-0.49-0.189.4511.14.85.07
Upgrade
Operating Income
0.490.18-9.45-11.1-4.8-5.07
Upgrade
Interest Expense
-2.93-0.23-0.21-0.15-0.01-0.18
Upgrade
Currency Exchange Gain (Loss)
0.120.12-0.270.05-0.05-0.01
Upgrade
Other Non Operating Income (Expenses)
2.712.710.5214.02-17.30.63
Upgrade
EBT Excluding Unusual Items
0.382.79-9.412.82-22.17-4.63
Upgrade
Merger & Restructuring Charges
-----0.11-6.92
Upgrade
Asset Writedown
-15.63-15.63-33.77-2.49--
Upgrade
Other Unusual Items
12.1712.1717.346.51-9.58-
Upgrade
Pretax Income
-3.08-0.67-25.836.84-31.86-11.55
Upgrade
Income Tax Expense
-4.88-4.88-4.62-0.1--
Upgrade
Net Income
-4.724.21-21.216.94-31.86-11.55
Upgrade
Net Income to Common
-4.724.21-21.216.94-31.86-11.55
Upgrade
Shares Outstanding (Basic)
3527221061
Upgrade
Shares Outstanding (Diluted)
3527221161
Upgrade
Shares Change (YoY)
33.44%18.94%105.55%75.89%322.12%39.75%
Upgrade
EPS (Basic)
-0.130.16-0.950.71-5.13-7.86
Upgrade
EPS (Diluted)
-0.130.16-0.95-0.20-5.20-7.86
Upgrade
Free Cash Flow
-0.95-0.31-6.48-4.85-5.56-1.64
Upgrade
Free Cash Flow Per Share
-0.03-0.01-0.29-0.44-0.90-1.11
Upgrade
EBITDA
-----4.78-5.05
Upgrade
D&A For EBITDA
----0.020.02
Upgrade
EBIT
0.490.18-9.45-11.1-4.8-5.07
Upgrade
Updated Nov 29, 2021. Source: S&P Global Market Intelligence. Standard template. Financial Sources.